A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.

A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection. Clin Infect Dis. 2019 09 13; 69(7):1165-1172.

View in: PubMed

subject areas

Adult
Anti-Inflammatory Agents
Antiretroviral Therapy, Highly Active
Biomarkers
CD4 Lymphocyte Count
Female
HIV
HIV Infections
Humans
Immunologic Factors
Male
Middle Aged
Sitagliptin Phosphate
Treatment Outcome
Viral Load

authors with profiles

Alan L. Landay